Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, Jeremy M. Pantin, Rasmus T. Hoeg, Lori S. Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, J. Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 230.

https://doi.org/10.1182/blood-2023-186749

Published: 2023

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Arpita Gandhi, Rasmus T. Hoeg, Sagar S. Patel, Edmund K. Waller, Jeremy M. Pantin, Caspian H. Oliai, J. Scott McClellan, Anna Pavlova, Irene Agodoa, Nathaniel B. Fernhoff, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2023-188994

Published: 2023

Journal Articles

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3504.

https://doi.org/10.1182/blood-2023-190388

Published: 2023

Journal Articles

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Blood (2022) 140 (Supplement 1): 654–656.

https://doi.org/10.1182/blood-2022-165654

Published: 2022

Journal Articles

A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE) (NCT05181540) - Trials in Progress

Michael Scordo, Geoffrey Shouse, Luke Mountjoy, Jordan Gauthier, Bhagirathbhai Dholaria, Scott D. Rowley, Jeremy M. Pantin, Zachariah Defilipp, Monica Mead, Paul Finnegan

Blood (2022) 140 (Supplement 1): 10573–10574.

https://doi.org/10.1182/blood-2022-162373

Published: 2022

Journal Articles

Real World Use of Narsoplimab in a Case of Severe HSCT-TMA

Jeremy M. Pantin, Augustus Billy

Blood (2021) 138 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2021-148688

Published: 2021

Journal Articles

Antibody Response to Pneumococcal Conjugate Vaccine (PCV13) in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Benjamin Andrick, Pharm.D., Abulrahman Alwhaibi, Pharm.D., David DeRemer, Pharm.D., BCOP, FCCP, Sameera Quershi, BS, Rahil Khan, BS, MPH, Somanath Shenoy, PhD, FAHA, Jeremy M Pantin, MD

Blood (2016) 128 (22): 5597.

https://doi.org/10.1182/blood.V128.22.5597.5597

Published: 2016

Journal Articles

CX-01, a Low Anticoagulant Heparin, May Enhance Count Recovery and Treatment Efficacy in Acute Myeloid Leukemia

Tibor J. Kovacsovics, MD, Alice S. Mims, MD MSCR, Mohamed E Salama, MD, Jeremy M Pantin, MD, Ken M Kosak, B.S., Narayanam Rao, PhD, Peter Ahorukomeye, Martha Glenn, MD, Michael W. Deininger, MD PhD, Kenneth M Boucher, PhD, Linda M Bavisotto, MD, Gerardo Gutierrez-Sanchez, PhD, Thomas P Kennedy, MD MPH, Stephen Garrett Marcus, MD, Paul J Shami, MD

Blood (2016) 128 (22): 5220.

https://doi.org/10.1182/blood.V128.22.5220.5220

Published: 2016

Journal Articles

Excellent Outcomes of Combined Haploidentical and Cord-Blood (Haplo-Cord) Transplantation and HLA-Matched Sibling (Matched-Sib) Donor Transplantation for High-Risk Patients with Severe Aplastic Anemia (SAA) Refractory to Immunosuppressive Therapy

Blood (2016) 128 (22): 4689.

https://doi.org/10.1182/blood.V128.22.4689.4689

Published: 2016

Journal Articles

Excellent Engraftment and Reduced Acute and Chronic Graft Versus Host Disease (GVHD) in ATG-Refractory Severe Aplastic Anemia (SAA) Following Transplantation of a PBSC Allograft Containing CD34+ Selected Cells Combined with Non-Mobilized Donor T-Cells

Enkhtsetseg Purev, Xin Tian, Jeremy M Pantin, Robert N Reger, Lisa Cook, Catalina Ramos, Elena Cho, Sneha Purvey, Patricia Prince, Hahn Khuu, David Stroncek, Susan Leitman, Danielle M. Townsley, MD, Neal S. Young, MD, Georg Aue, Richard W. Childs, MD

Blood (2014) 124 (21): 3882.

https://doi.org/10.1182/blood.V124.21.3882.3882

Published: 2014

Journal Articles

Preliminary Evidence That ODSH (2-O, 3-O Desulfated Heparin) Is Safe and Enhances Count Recovery in Patients Treated with Intensive Therapy for Acute Myeloid Leukemia – Results of a Pilot Study

Tibor J. Kovacsovics, MD, Alice Mims, MD, Mohamed E Salama, MD, Jeremy M Pantin, Michael W. Deininger, Thomas P Kennedy, MD, Linda M Bavisotto, MD, Kenneth M Boucher, PhD, Stephen G Marcus, MD, Paul J Shami, MD

Blood (2014) 124 (21): 5297.

https://doi.org/10.1182/blood.V124.21.5297.5297

Published: 2014

Journal Articles

Optimization of an Intra-Bone Hematopoietic Stem Cell Delivery Technique in a Swine Model.

Jeremy M Pantin, MB.BS., Robert F Hoyt, Jr., DVM, Omer Aras, MD, Marcus Y Chen, MD, Noriko Sato, MD, PhD, Peter Choyke, MD, Richard Childs, MD

Blood (2012) 120 (21): 2990.

https://doi.org/10.1182/blood.V120.21.2990.2990

Published: 2012

Journal Articles

A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL)

Anand P. Jillella, MD, Farrukh Awan, MD, MS, Ravindra B. Kolhe, MD, PhD, Jeremy M Pantin, MB.BS., Devi D Morrison, Vamsi Kota, MBBS

Blood (2012) 120 (21): 4317.

https://doi.org/10.1182/blood.V120.21.4317.4317

Published: 2012

Journal Articles

High Dose Plerixafor Is Safe and Mobilizes Higher Numbers of CD34+ Cells Compared with Standard Dose Plerixafor

Jeremy M Pantin, MB.BS., Xin Tian, Ph.D., Matthew M. Hsieh, MD, Lisa Cook, RN, BSN, Theresa Donohue, MHS, PA-C, Elena Cho, RN MSN, Aleah Smith, Robert Reger, Thomas Trischman, PhD, Hanh Khuu, MD, Richard Childs, MD

Blood (2012) 120 (21): 585.

https://doi.org/10.1182/blood.V120.21.585.585

Published: 2012

NARROW

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Real World Use of Narsoplimab in a Case of Severe HSCT-TMA

Antibody Response to Pneumococcal Conjugate Vaccine (PCV13) in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

CX-01, a Low Anticoagulant Heparin, May Enhance Count Recovery and Treatment Efficacy in Acute Myeloid Leukemia

Excellent Outcomes of Combined Haploidentical and Cord-Blood (Haplo-Cord) Transplantation and HLA-Matched Sibling (Matched-Sib) Donor Transplantation for High-Risk Patients with Severe Aplastic Anemia (SAA) Refractory to Immunosuppressive Therapy

Excellent Engraftment and Reduced Acute and Chronic Graft Versus Host Disease (GVHD) in ATG-Refractory Severe Aplastic Anemia (SAA) Following Transplantation of a PBSC Allograft Containing CD34+ Selected Cells Combined with Non-Mobilized Donor T-Cells

Preliminary Evidence That ODSH (2-O, 3-O Desulfated Heparin) Is Safe and Enhances Count Recovery in Patients Treated with Intensive Therapy for Acute Myeloid Leukemia – Results of a Pilot Study

Optimization of an Intra-Bone Hematopoietic Stem Cell Delivery Technique in a Swine Model.

A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL)

High Dose Plerixafor Is Safe and Mobilizes Higher Numbers of CD34+ Cells Compared with Standard Dose Plerixafor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only